ResearcherNational Institutes for Quantum Science and TechnologyNo recent work listed

Yoichi Takakusagi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6786-0748; OpenAlex author ID A5011980329. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2022: 1 paper

Papers 1

The natural sulfoglycolipid derivative SQAP improves the therapeutic efficacy of tissue factor-targeted radioimmunotherapy in the stroma-rich pancreatic cancer… Co-author DOI 10.1016/j.tranon.2021.101285 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Aya Sugyo · 1 shared paper, 2022 · strength 0.16
- Paper The natural sulfoglycolipid derivative SQAP improves the therapeutic efficacy of tissue factor-targeted radioimmunother… DOI 10.1016/j.tranon.2021.101285 ↗
Masahiro Yasunaga · 1 shared paper, 2022 · strength 0.16
- Paper The natural sulfoglycolipid derivative SQAP improves the therapeutic efficacy of tissue factor-targeted radioimmunother… DOI 10.1016/j.tranon.2021.101285 ↗
Yasuhiro Matsumura · 1 shared paper, 2022 · strength 0.16
- Paper The natural sulfoglycolipid derivative SQAP improves the therapeutic efficacy of tissue factor-targeted radioimmunother… DOI 10.1016/j.tranon.2021.101285 ↗
Tatsuya Higashi · 1 shared paper, 2022 · strength 0.16
- Paper The natural sulfoglycolipid derivative SQAP improves the therapeutic efficacy of tissue factor-targeted radioimmunother… DOI 10.1016/j.tranon.2021.101285 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.